Evaluation of the Effectiveness and Safety of Adding Ivermectin to Treatment in Severe COVID-19 Patients

DOI record: { "DOI": "10.1186/s12879-021-06104-9", "ISSN": [ "1471-2334" ], "URL": "http://dx.doi.org/10.1186/s12879-021-06104-9", "abstract": "<jats:title>Abstract</jats:title><jats:sec>\n <jats:title>Background and objectives</jats:title>\n <jats:p>An effective treatment option is not yet available for SARS-CoV2, which causes the COVID-19 pandemic and whose effects are felt more and more every day. Ivermectin is among the drugs whose effectiveness in treatment has been investigated. In this study; it was aimed to investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Materials and methods</jats:title>\n <jats:p>Patients with severe COVID19 pneumonia were included in the study, which was planned as a prospective, randomized, controlled, single-blind phase 3 study. Two groups, the study group and the control group, took part in the study. Ivermectin 200 mcg/kg/day for 5 days in the form of a solution prepared for enteral use added to the reference treatment protocol -hydroxychloroquine + favipiravir + azithromycin- of patients included in the study group. Patients in the control group were given only reference treatment with 3 other drugs without ivermectin. The presence of mutations was investigated by performing sequence analysis in the <jats:italic>mdr1/abcab1</jats:italic> gene with the Sanger method in patients included in the study group according to randomization. Patients with mutations were excluded from the study and ivermectin treatment was not continued. Patients were followed for 5 days after treatment. At the end of the treatment and follow-up period, clinical response and changes in laboratory parameters were evaluated.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>A total of 66 patients, 36 in the study group and 30 in the control group were included in the study. Mutations affecting ivermectin metabolism was detected in genetic tests of six (16.7%) patients in the study group and they were excluded from the study. At the end of the 5-day follow-up period, the rate of clinical improvement was 73.3% (22/30) in the study group and was 53.3% (16/30) in the control group (<jats:italic>p = 0.10</jats:italic>). At the end of the study, mortality developed in 6 patients (20%) in the study group and in 9 (30%) patients in the control group (<jats:italic>p = 0.37</jats:italic>). At the end of the follow-up period, the average peripheral capillary oxygen saturation (SpO2) values of the study and control groups were found to be 93.5 and 93.0%, respectively. Partial pressure of oxygen (PaO2)/FiO2 ratios were determined as 236.3 ± 85.7 and 220.8 ± 127.3 in the study and control groups, respectively. While the blood lymphocyte count was higher in the study group compared to the control group (1698 ± 1438 and 1256 ± 710, respectively) at the end of the follow-up period (<jats:italic>p = 0.24</jats:italic>); reduction in serum C-reactive protein (CRP), ferritin and D-dimer levels was more pronounced in the study group (<jats:italic>p = 0.02, p = 0.005 and p = 0.03</jats:italic>, respectively).</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Conclusions</jats:title>\n <jats:p>According to the findings obtained, ivermectin can provide an increase in clinical recovery, improvement in prognostic laboratory parameters and a decrease in mortality rates even when used in patients with severe COVID-19. Consequently, ivermectin should be considered as an alternative drug that can be used in the treatment of COVID-19 disease or as an additional option to existing protocols.</jats:p>\n </jats:sec>", "alternative-id": [ "6104" ], "article-number": "411", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "8 February 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "15 April 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "4 May 2021" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Ethics approval and consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "Ethics board approval (Afyonkarahisar Health Science University, Local Ethical Commitee 03.04.2020/139). All participants provided informed consent prior to study enrollment." }, { "group": { "label": "Consent for publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "Not applicable." }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 4, "value": "The authors declare that they have neither financial nor non-financial competing interests." } ], "author": [ { "affiliation": [], "family": "Okumuş", "given": "Nurullah", "sequence": "first" }, { "affiliation": [], "family": "Demirtürk", "given": "Neşe", "sequence": "additional" }, { "affiliation": [], "family": "Çetinkaya", "given": "Rıza Aytaç", "sequence": "additional" }, { "affiliation": [], "family": "Güner", "given": "Rahmet", "sequence": "additional" }, { "affiliation": [], "family": "Avcı", "given": "İsmail Yaşar", "sequence": "additional" }, { "affiliation": [], "family": "Orhan", "given": "Semiha", "sequence": "additional" }, { "affiliation": [], "family": "Konya", "given": "Petek", "sequence": "additional" }, { "affiliation": [], "family": "Şaylan", "given": "Bengü", "sequence": "additional" }, { "affiliation": [], "family": "Karalezli", "given": "Ayşegül", "sequence": "additional" }, { "affiliation": [], "family": "Yamanel", "given": "Levent", "sequence": "additional" }, { "affiliation": [], "family": "Kayaaslan", "given": "Bircan", "sequence": "additional" }, { "affiliation": [], "family": "Yılmaz", "given": "Gülden", "sequence": "additional" }, { "affiliation": [], "family": "Savaşçı", "given": "Ümit", "sequence": "additional" }, { "affiliation": [], "family": "Eser", "given": "Fatma", "sequence": "additional" }, { "affiliation": [], "family": "Taşkın", "given": "Gürhan", "sequence": "additional" } ], "container-title": "BMC Infectious Diseases", "container-title-short": "BMC Infect Dis", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 5, 4 ] ], "date-time": "2021-05-04T08:04:55Z", "timestamp": 1620115495000 }, "deposited": { "date-parts": [ [ 2021, 5, 5 ] ], "date-time": "2021-05-05T00:03:08Z", "timestamp": 1620172988000 }, "indexed": { "date-parts": [ [ 2024, 4, 8 ] ], "date-time": "2024-04-08T20:30:56Z", "timestamp": 1712608256183 }, "is-referenced-by-count": 63, "issue": "1", "issued": { "date-parts": [ [ 2021, 5, 4 ] ] }, "journal-issue": { "issue": "1", "published-print": { "date-parts": [ [ 2021, 12 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 5, 4 ] ], "date-time": "2021-05-04T00:00:00Z", "timestamp": 1620086400000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 5, 4 ] ], "date-time": "2021-05-04T00:00:00Z", "timestamp": 1620086400000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1186/s12879-021-06104-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1186/s12879-021-06104-9/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1186/s12879-021-06104-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1186", "published": { "date-parts": [ [ 2021, 5, 4 ] ] }, "published-online": { "date-parts": [ [ 2021, 5, 4 ] ] }, "published-print": { "date-parts": [ [ 2021, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1056/NEJMoa2002032", "author": "WJ Guan", "doi-asserted-by": "publisher", "first-page": "1708", "issue": "18", "journal-title": "N Engl J Med", "key": "6104_CR1", "unstructured": "Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032.", "volume": "382", "year": "2020" }, { "key": "6104_CR2", "unstructured": "WHO Coronavirus Disease (COVID-19) Dashboard available at https://COVID-19.who.int/." }, { "DOI": "10.1016/j.jmii.2020.03.034", "author": "SS Jean", "doi-asserted-by": "publisher", "first-page": "436", "issue": "3", "journal-title": "J Microbiol Immunol Infect", "key": "6104_CR3", "unstructured": "Jean SS, Lee PI, Husueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43. https://doi.org/10.1016/j.jmii.2020.03.034.", "volume": "53", "year": "2020" }, { "DOI": "10.1155/2016/8043983", "author": "R Croci", "doi-asserted-by": "publisher", "first-page": "8043983", "journal-title": "Int J Biomater", "key": "6104_CR4", "unstructured": "Croci R, Bottaro E, Chan KWK, Watanabe S, Pezzullo M, Mastrangelo E, et al. Liposomal systems as Nanocarriers for the antiviral agent Ivermectin. Int J Biomater. 2016;2016:8043983–15. https://doi.org/10.1155/2016/8043983.", "volume": "2016", "year": "2016" }, { "DOI": "10.1093/jac/dks147", "author": "E Mastrangelo", "doi-asserted-by": "publisher", "first-page": "1884", "issue": "8", "journal-title": "J Antimicrob Chemother", "key": "6104_CR5", "unstructured": "Mastrangelo E, Pezzullo M, Burghgraeve TD, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase aactivity: new prospects for an old drug. J Antimicrob Chemother. 2012;67(8):1884–94. https://doi.org/10.1093/jac/dks147.", "volume": "67", "year": "2012" }, { "DOI": "10.1038/s41429-020-0336-z", "author": "F Heidary", "doi-asserted-by": "publisher", "first-page": "593", "issue": "9", "journal-title": "J Antibiot", "key": "6104_CR6", "unstructured": "Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot. 2020;73(9):593–602. https://doi.org/10.1038/s41429-020-0336-z.", "volume": "73", "year": "2020" }, { "DOI": "10.1016/j.antiviral.2020.104787", "author": "L Caly", "doi-asserted-by": "publisher", "first-page": "104787", "journal-title": "Antivir Res", "key": "6104_CR7", "unstructured": "Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The-FDA approved drug ivermektin inhibits the replication of SARSCoV-2 in vitro. Antivir Res. 2020;178:104787. https://doi.org/10.1016/j.antiviral.2020.104787 Epub 2020 Apr 3.", "volume": "178", "year": "2020" }, { "DOI": "10.4269/ajtmh.17-0042", "author": "RE Chandler", "doi-asserted-by": "publisher", "first-page": "382", "issue": "2", "journal-title": "Am J Trop Med Hyg", "key": "6104_CR8", "unstructured": "Chandler RE. Serious neurological adverse events after Ivermectin- do they occur beyond the indication of Onchocerciasis? Am J Trop Med Hyg. 2018;98(2):382–8. https://doi.org/10.4269/ajtmh.17-0042.", "volume": "98", "year": "2018" }, { "DOI": "10.1038/s41598-018-30907-7", "author": "VLL Gall", "doi-asserted-by": "publisher", "first-page": "12401", "issue": "1", "journal-title": "Sci Rep", "key": "6104_CR9", "unstructured": "Gall VLL, Klafke GM, Torres TT. Detoxification mechanisms involved in ivermectin resistance in the cattle tick , Rhipicephalus (Boophilus) microplus. Sci Rep. 2018;8(1):12401. https://doi.org/10.1038/s41598-018-30907-7.", "volume": "8", "year": "2018" }, { "author": "P Sun", "first-page": "612", "issue": "6", "journal-title": "J MedVirol", "key": "6104_CR10", "unstructured": "Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J MedVirol. 2020;92(6):612–7.", "volume": "92", "year": "2020" }, { "DOI": "10.26355/eurrev_202002_20379", "author": "SA Meo", "doi-asserted-by": "publisher", "first-page": "2012", "issue": "4", "journal-title": "Eur Rev Med Pharmacol Sci", "key": "6104_CR11", "unstructured": "Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–9. https://doi.org/10.26355/eurrev_202002_20379.", "volume": "24", "year": "2020" }, { "DOI": "10.1056/NEJMoa2004500", "author": "PK Bhatraju", "doi-asserted-by": "publisher", "first-page": "2012", "issue": "21", "journal-title": "NEJM", "key": "6104_CR12", "unstructured": "Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle Region- Case Series. NEJM. 2020;382(21):2012–22.", "volume": "382", "year": "2020" }, { "DOI": "10.1016/S2213-2600(20)30079-5", "author": "X Yang", "doi-asserted-by": "publisher", "first-page": "475", "issue": "5", "journal-title": "Lancet Respir Med", "key": "6104_CR13", "unstructured": "Yang X, Yu Y, Xu J, Shu H, Xia J', Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81. https://doi.org/10.1016/S2213-2600(20)30079-5.", "volume": "8", "year": "2020" }, { "DOI": "10.1186/s13054-020-03098-9", "author": "J Xu", "doi-asserted-by": "publisher", "first-page": "394", "issue": "1", "journal-title": "Crit Care", "key": "6104_CR14", "unstructured": "Xu J, Yang X, Yang L, Zou X, Wang Y, Wu Y, et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care. 2020;24(1):394. https://doi.org/10.1186/s13054-020-03098-9.", "volume": "24", "year": "2020" }, { "DOI": "10.1016/j.ijid.2020.03.017", "author": "J Yang", "doi-asserted-by": "publisher", "first-page": "91", "journal-title": "Int J Infect Dis", "key": "6104_CR15", "unstructured": "Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5. https://doi.org/10.1016/j.ijid.2020.03.017.", "volume": "94", "year": "2020" }, { "DOI": "10.26355/eurrev_202004_21038", "author": "SA Meo", "doi-asserted-by": "publisher", "first-page": "4539", "issue": "8", "journal-title": "Eur Rev Med Pharmacol Sci", "key": "6104_CR16", "unstructured": "Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020;24(8):4539–47. https://doi.org/10.26355/eurrev_202004_21038.", "volume": "24", "year": "2020" }, { "DOI": "10.1056/NEJMoa2001282", "author": "B Cao", "doi-asserted-by": "publisher", "first-page": "1787", "issue": "19", "journal-title": "NEJM", "key": "6104_CR17", "unstructured": "Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults in hospitalized with severe Covid-19. NEJM. 2020;382(19):1787–99. https://doi.org/10.1056/NEJMoa2001282.", "volume": "382", "year": "2020" }, { "DOI": "10.1056/NEJMoa2007764", "author": "JH Beigel", "doi-asserted-by": "publisher", "first-page": "1813", "issue": "19", "journal-title": "N Engl J Med", "key": "6104_CR18", "unstructured": "Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19. Final report. N Engl J Med. 2020;383(19):1813–26. https://doi.org/10.1056/NEJMoa2007764.", "volume": "383", "year": "2020" }, { "DOI": "10.1093/cid/ciaa1176", "author": "AA Ivashchenko", "doi-asserted-by": "publisher", "first-page": "ciaa1176", "journal-title": "Clin Infect Dis", "key": "6104_CR19", "unstructured": "Ivashchenko AA, Dimitriev KA, Vostokova NV, et al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2020;9:ciaa1176. https://doi.org/10.1093/cid/ciaa1176 CID. Online ahead of print.", "volume": "9", "year": "2020" }, { "DOI": "10.1101/2020.06.06.20124461", "doi-asserted-by": "publisher", "key": "6104_CR20", "unstructured": "Rajter JC, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter J-J. ICON (ivermectin in COvid nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. medRxiv. 2020; https://doi.org/10.1101/2020.06.06.20124461." }, { "DOI": "10.18632/aging.103745", "author": "Y Liu", "doi-asserted-by": "publisher", "first-page": "15946", "issue": "16", "journal-title": "Aging", "key": "6104_CR21", "unstructured": "Liu Y, Liu L, Wang Y, Du X, Ma H, Yao J. Clinical course and characteristics of patients with coronavirus disease 2019 in Wuhan, China: a single-centered, retrospective, observational study. Aging. 2020;12(16):15946–53. https://doi.org/10.18632/aging.103745 Epub 2020 Aug 24.", "volume": "12", "year": "2020" }, { "DOI": "10.1016/j.ejim.2020.05.009", "author": "R Capra", "doi-asserted-by": "publisher", "first-page": "31", "journal-title": "Eur J Intern Med", "key": "6104_CR22", "unstructured": "Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31–5. https://doi.org/10.1016/j.ejim.2020.05.009.", "volume": "76", "year": "2020" }, { "DOI": "10.1016/j.nmni.2020.100684", "author": "R Choudhary", "doi-asserted-by": "publisher", "first-page": "100684", "journal-title": "New Microbes New Infect", "key": "6104_CR23", "unstructured": "Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020;35:100684. https://doi.org/10.1016/j.nmni.2020.100684 PMID: 32322397; PMCID: PMC7175902.", "volume": "35", "year": "2020" }, { "DOI": "10.1016/j.pulmoe.2020.04.013", "author": "JC Winck", "doi-asserted-by": "publisher", "first-page": "213", "issue": "4", "journal-title": "Pulmonology", "key": "6104_CR24", "unstructured": "Winck JC, Ambrosino N. COVID-19 pandemic and noninvasive respiratory management: every goliath needs a David: an evidence based evaluation of problems. Pulmonology. 2020;26(4):213–20. https://doi.org/10.1016/j.pulmoe.2020.04.013.", "volume": "26", "year": "2020" }, { "author": "SX Zhang", "first-page": "431", "issue": "5", "journal-title": "ZhonghuaLie He He Hu XizaZhi", "key": "6104_CR25", "unstructured": "Zhang SX, Li J, Zhou P, et al. The analysis of clinical characteristics of 34 novel coronovirus pneumonia cases in Ningxia Huiautonomous region. ZhonghuaLie He He Hu XizaZhi. 2020;43(5):431–6.", "volume": "43", "year": "2020" }, { "DOI": "10.1515/cclm-2020-0369", "author": "BM Henry", "doi-asserted-by": "publisher", "first-page": "1021", "issue": "7", "journal-title": "Clin Chem Lab Med", "key": "6104_CR26", "unstructured": "Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–8. https://doi.org/10.1515/cclm-2020-0369.", "volume": "58", "year": "2020" }, { "author": "M Fei", "first-page": "554", "issue": "5", "journal-title": "Zhonghua Wei Zhong Bing Ji Jiu Xue", "key": "6104_CR27", "unstructured": "Fei M, Tong F, Tao X, Wang J. Value of neutrophil-to-lymphocyte ratio in the classification diagnosis of coronavirus disease 2019. Zhonghua Wei Zhong Bing Ji Jiu Xue. 2020;32(5):554–8.", "volume": "32", "year": "2020" }, { "DOI": "10.1186/s12967-020-02374-0", "author": "J Liu", "doi-asserted-by": "publisher", "first-page": "206", "issue": "1", "journal-title": "J Transl Med", "key": "6104_CR28", "unstructured": "Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil to lymphocyte ratio predicts critical illnes patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206. https://doi.org/10.1186/s12967-020-02374-0.", "volume": "18", "year": "2020" }, { "DOI": "10.1186/s12931-020-01428-7", "author": "Y Wenjing", "doi-asserted-by": "publisher", "first-page": "169", "issue": "1", "journal-title": "Respir Res", "key": "6104_CR29", "unstructured": "Wenjing Y, Chen G, Li X, et al. Dynamic changes of D-dimer and neutrophil-lymphocyte countr atio as prognostic biomarkers in COVID-19. Respir Res. 2020;21(1):169.", "volume": "21", "year": "2020" }, { "DOI": "10.1002/jmv.25843", "author": "AK Mishra", "doi-asserted-by": "publisher", "first-page": "1419", "issue": "9", "journal-title": "J Med Virol", "key": "6104_CR30", "unstructured": "Mishra AK, Sahu KK, Lal A. Reporting of all cardiac medications and their outcome in COVID-19. J Med Virol. 2020;92(9):1419–20. https://doi.org/10.1002/jmv.25843.", "volume": "92", "year": "2020" } ], "reference-count": 30, "references-count": 30, "relation": { "has-preprint": [ { "asserted-by": "object", "id": "10.21203/rs.3.rs-224203/v1", "id-type": "doi" } ] }, "resource": { "primary": { "URL": "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06104-9" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases" ], "subtitle": [], "title": "Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "21" }